Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Acquired Resistance
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
Anakinra
33%
Antimicrobial Prophylaxis
33%
AUC24h
26%
Autologous Stem Cell Transplantation (auto-SCT)
33%
Bordetella Bronchiseptica
33%
Clinical Practice
33%
Cmin
33%
Community-acquired Respiratory Viral Infection
33%
Cytomegalovirus
26%
Dose Adjustment
13%
Dosing Regimen
20%
Fever
38%
Fixed-dose Regimen
33%
Ganciclovir
66%
Heart Transplant Recipients
11%
Hematopoietic Stem Cell Transplant
33%
High-dose Melphalan
14%
HIV Patients
11%
Immunocompromised Patients
11%
Laboratory Measurements
33%
Load Estimation
11%
Longitudinal Analysis
33%
Lung Transplantation
33%
Mucositis
33%
Multiple Myeloma
11%
Neutropenia
33%
Optimized Dosing Regimen
33%
Parainfluenza Virus Type 3
33%
Paramyxovirus
33%
Posaconazole
33%
Practice Analysis
33%
Preemptive Therapy
33%
Randomized Placebo-controlled Trial
33%
Recipient Evaluation
33%
Ribavirin
33%
Routine Laboratory
33%
Secondary Outcome Measures
13%
Solid Organ
11%
Solid Stem
11%
Therapeutic Drug Monitoring
100%
Thymoma
11%
Transplant Patients
13%
Transplant Recipients
66%
Underexposure
13%
Vaccine Strain
33%
Viral Load
11%
Weight-based
23%
Zoonotic Transmission
33%
Immunology and Microbiology
Anakinra
33%
Arm
16%
Attenuated Vaccine
11%
Autologous Hematopoietic Stem Cell Transplantation
16%
Autologous Stem Cell Transplantation
33%
Awareness
11%
Bordetella bronchiseptica
33%
Breakthrough Infection
33%
Cohort Effect
5%
Cytomegalovirus
16%
Dog
11%
Drug Dose Reduction
16%
Drug Megadose
22%
Embase
16%
Hemagglutinin-Neuraminidase
11%
Hematopoietic Stem Cell Transplantation
11%
Human Parainfluenza Virus 3
33%
Infection
94%
Infectious Disease
94%
Influenza
5%
Interleukin 1
11%
Interleukin 1 Receptor Antagonist
5%
Live Vaccine
11%
Lymphocytopenia
5%
Maximum Tolerated Dose
5%
Metapneumovirus
5%
Microflora
5%
Molecular Epidemiology
33%
Morbidity
12%
Mortality Rate
5%
Multiple Myeloma
16%
Opportunistic Infection
16%
Parainfluenza
5%
Paramyxovirinae
5%
Preclinical Study
5%
Proinflammatory Cytokine
5%
Respiratory Syncytial Virus
5%
Respiratory Virus
37%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Stem Cell Transplant
16%
Viral Disease
33%
Virus
5%
Zoonotic
33%
Pharmacology, Toxicology and Pharmaceutical Science
Anakinra
33%
C Reactive Protein
11%
Chemotherapy Regimens
6%
Cmin
33%
Cytomegalovirus
22%
Ganciclovir
66%
HIV
11%
Immunocompromised Patient
11%
Infection
5%
Inflammation
33%
Interleukin 1
6%
Melphalan
12%
Mucosa Inflammation
33%
Multiple Myeloma
9%
Mycosis
5%
Neutropenia
33%
Observational Study
9%
Paramyxovirus Infection
33%
Placebo
33%
Posaconazole
66%
Prospective Study
40%
Ribavirin
33%
Therapeutic Drug Monitoring
100%
Therapeutic Window
5%
Thymus Cancer
11%
